A randomized, molecular driven phase II trial of Carboplatin-Paclitaxel-
Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, selected according to HRD status, in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination.
Trial Number
NCT03462212 (ClinicalTrials.gov Identifier)Contact Person
Status
Closed to Recruitment
Disease Site
Ovarian
Lead Cooperative Group
Participating Groups
MaNGO